Upcoming catalysts for the second quarter of 2023 include approval decisions by the US FDA on obeticholic acid for non-alcoholic steatohepatitis (NASH), odevixibat for Alagille syndrome and palopegteriparatide for hypoparathyroidism.

The author declares no competing interests.